NewAmsterdam Pharma Company N.V.
Organization details
- Legal name
- NewAmsterdam Pharma Company N.V.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Netherlands
- Headquarters city
- Narrden
- Headquarters country
- Netherlands
- Fiscal year end
- December
- Ticker symbol
- NAMS
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001936258
Board of directors
-
Adele M. Gulfo · DirectorSince 2025
-
Der Kamp Hilde Johanna Van · DirectorSince 2023
-
Hugo Alexander Slootweg · DirectorSince 2023
-
James N. Topper · DirectorSince 2023
-
Johannes Jacob Pieter Kastelein · Director · Chief Scientific OfficerSince 2023
-
John W. Smither · DirectorSince 2023
-
Juliette Berangere Audet · DirectorSince 2023
-
Louis G. Lange · DirectorSince 2023
- Since 2024
-
Michael H. Davidson · Director · Chief Executive OfficerSince 2023
-
Nicholas Downing · DirectorSince 2023
-
William Lewis · DirectorSince 2024
-
Wouter Joustra · DirectorSince 2024
Chief executives
Weak · grade F
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 0
-39.7% a year in revenue
20% of the scoring weight is on file. Figures cover December 2022 – December 2025.
Director election results
Annual meeting of June 2, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
98.9%
Board connections
9 of this board's directors also sit on 19 other boards. 16 are in the same sector.
-
Attovia Therapeutics Inc. Same sectorvia James N. Topper and John W. Smither
-
AnaptysBio Inc. Same sectorvia James N. Topper
-
BioAge Labs Inc. Same sectorvia Michael H. Davidson
-
BridgeBio Oncology Therapeutics Inc. Same sectorvia Mark C. McKenna
- via Adele M. Gulfo
-
Freenome Inc. Same sectorvia Mark C. McKenna
-
Genelux Corporation Same sectorvia John W. Smither
-
Heartflow Inc. Same sectorvia Nicholas Downing
- via Mark C. McKenna
-
Insmed Incorporated Same sectorvia William Lewis
-
Phathom Pharmaceuticals Inc. Same sectorvia James N. Topper
-
Replimune Group Inc. Same sectorvia Hugo Alexander Slootweg
- via Michael H. Davidson
-
Spyre Therapeutics Inc. Same sectorvia Mark C. McKenna
- via Mark C. McKenna
-
Tenax Therapeutics Inc. Same sectorvia Michael H. Davidson
-
Tyra Biosciences Inc. Same sectorvia Adele M. Gulfo
-
Vor Biopharma Inc. Same sectorvia Wouter Joustra
-
enGene Therapeutics Inc. Same sectorvia Wouter Joustra
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $226,500
- 1 purchase by 1 insider
- Sold, last 12 months
- $63,253,727
- 43 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 30, 2026 | Johannes Jacob Pieter Kastelein Director, Officer (Chief Scientific Officer) | Option exercise | +50,246 | — | — |
| Sep 30, 2026 | Johannes Jacob Pieter Kastelein Director, Officer (Chief Scientific Officer) | Open-market sale | −50,246 | $25.03 | $1,257,657 |
| Sep 14, 2026 | Michael H. Davidson Director, Officer (Chief Executive Officer) | Open-market purchase | +10,000 | $22.65 | $226,500 |
| Sep 4, 2026 | John W. Smither Director | Open-market sale | −1,600 | $25.32 | $40,512 |
| Sep 1, 2026 | Gunning Robert William Officer (Vice President, Controller) | Grant or award | +3,200 | — | — |
| Aug 24, 2026 | Johannes Jacob Pieter Kastelein Director, Officer (Chief Scientific Officer) | Option exercise | +125,000 | — | — |
| Aug 24, 2026 | Johannes Jacob Pieter Kastelein Director, Officer (Chief Scientific Officer) | Open-market sale | −125,000 | $26.91 | $3,363,750 |
| Jul 20, 2026 | Kooij Louise Frederika Officer (Chief Accounting Officer) | Option exercise | +25,000 | $11.90 | $297,500 |
| Jul 20, 2026 | Kooij Louise Frederika Officer (Chief Accounting Officer) | Option exercise | +80,000 | $11.17 | $893,600 |
| Jul 20, 2026 | Kooij Louise Frederika Officer (Chief Accounting Officer) | Open-market sale | −70,200 | $29.96 | $2,103,192 |
| Jul 20, 2026 | Kooij Louise Frederika Officer (Chief Accounting Officer) | Open-market sale | −31,885 | $31.05 | $990,029 |
| Jul 20, 2026 | Kooij Louise Frederika Officer (Chief Accounting Officer) | Open-market sale | −2,915 | $31.71 | $92,435 |
| Jun 22, 2026 | Kooij Louise Frederika Officer (Chief Accounting Officer) | Option exercise | +25,000 | $10.90 | $272,500 |
| Jun 22, 2026 | Kooij Louise Frederika Officer (Chief Accounting Officer) | Option exercise | +15,000 | $11.90 | $178,500 |
| Jun 22, 2026 | Kooij Louise Frederika Officer (Chief Accounting Officer) | Open-market sale | −39,700 | $30.20 | $1,198,940 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about NewAmsterdam Pharma Company N.V.
Who is the CEO of NewAmsterdam Pharma Company N.V.?
Michael H. Davidson has been NewAmsterdam Pharma Company N.V.'s Chief Executive Officer since December 2023.
How many directors are on NewAmsterdam Pharma Company N.V.'s board?
NewAmsterdam Pharma Company N.V.'s board has 13 directors: Adele M. Gulfo, Der Kamp Hilde Johanna Van, Hugo Alexander Slootweg, James N. Topper, Johannes Jacob Pieter Kastelein, John W. Smither, Juliette Berangere Audet, Louis G. Lange, Mark C. McKenna, Michael H. Davidson and 3 others.
Are NewAmsterdam Pharma Company N.V. insiders buying or selling shares?
Over the last 12 months, NewAmsterdam Pharma Company N.V. insiders bought $226,500 of shares in 1 purchase and sold $63.3 million of shares in 43 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="newamsterdam-pharma-company-nv"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.